Immunosuppressants - South Africa

South Africa

In South Africa, the Immunosuppressants market is anticipated to witness a significant growth in revenue, with projections indicating a reach of €103.60m in 2024.
This growth is expected to continue steadily, with an annual growth rate (CAGR 2024-2029) of 14.96%.
By 2029, the market volume is estimated to expand to €208.00m.
When compared globally, United States is expected to generate the highest revenue in the Immunosuppressants market, with a staggering €32,900.00m in 2024.
South Africa is experiencing an increasing demand for immunosuppressants due to a rise in organ transplantation surgeries.

Key regions: Australia, Germany, United Kingdom, United States, France

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Immunosuppressants market in South Africa has been showing steady growth in recent years.

Customer preferences: There is a growing demand for immunosuppressants in South Africa due to the increasing prevalence of autoimmune diseases and organ transplantation. Patients suffering from conditions such as rheumatoid arthritis, lupus, and multiple sclerosis require immunosuppressants to manage their symptoms. Additionally, the number of organ transplants performed in the country has been steadily increasing, which has also contributed to the growth of the market.

Trends in the market: The market for immunosuppressants in South Africa is expected to continue to grow due to the increasing prevalence of autoimmune diseases and organ transplantation. The market is also expected to benefit from the growing trend towards personalized medicine, which involves tailoring treatments to individual patients based on their genetic makeup and other factors. This trend is expected to drive demand for more targeted immunosuppressant therapies.

Local special circumstances: South Africa has a well-developed healthcare system, which includes both public and private healthcare facilities. The public healthcare system is funded by the government and provides free or low-cost healthcare to the majority of the population. The private healthcare system is funded by private insurance and caters to the more affluent segments of the population. The availability of immunosuppressants in South Africa is largely dependent on the public healthcare system, which provides the majority of healthcare services in the country.

Underlying macroeconomic factors: The South African economy has been experiencing slow growth in recent years, which has had a negative impact on the healthcare sector. The government has been working to address this issue by increasing healthcare spending and investing in healthcare infrastructure. Additionally, the country has a large and growing middle class, which is expected to drive demand for healthcare services, including immunosuppressants. Overall, the immunosuppressants market in South Africa is expected to continue to grow in the coming years, driven by increasing demand for these drugs and ongoing investments in the healthcare sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.